Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma Services AG
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with amlodipine 10 mg in patients with essential hypertension not adequately responsive to amlodipine 10 mg monotherapy
Demonstrate the efficacy of the combination therapies of aliskiren/amlodipine (150/10 mg and 300/10 mg), in hypertensive patients who do not adequately respond to a 4-week treatment of amlodipine 10 m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients
To assess the effect of MEK162 when administered b.i.d. for 6 months, on cardiac hypertrophy in Noonan syndrome patients with confirmed hypertrophic cardiomyopathy
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
The two co-primary objectives of this study are: • To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient’s assessment of gout pain intensity...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173
• To assess the safety and tolerability of CDZ173 in patients with primary Sjögren’s syndrome. • To compare the effect of CDZ173 versus placebo on the patient-reported outcomes of primary Sjögren’s s...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 treatment naive patients
Pharmacodynamics, Pharmacokinetic, safety profiles between treatment groups receiving 3 different doses of DEB025 in combination with RBV
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A one year extension study to CZOL446H2337, multi-center, to evaluate safety and efficacy of zoledronic acid given to all patients every six months in children with weakened bone treated with steroids
To demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent patients with persistent asthma
To evaluate the dose response relationship among four doses of indacaterol Twisthaler® (62.5, 125, 250, and 500 μg o.d.) and placebo as measured by the mean change from baseline to 24 hr post-dose of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects
The primary objective is to demonstrate the efficacy of a 28-day, twice-daily (BID) dosing regimen of TIP versus placebo, as measured by the relative change in forced expiratory volume at 1 second (FE...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Efficacy and safety of two different treatment patterns of ranibizumab in patients with wet AMD
The primary objective is to evaluate the effectiveness of two treatment regimens by assessing the average BCVA change from Month 4 to Month 12 compared to Month 3 based on both, BCVA stability in each...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A study to check how safe, beneficial and tolerable the drug canakinumab is for patients with Muckle-Wells Syndrome
This study is designed to provide efficacy and safety data for ACZ885 (a fully human anti-interleukin-1beta (anti-IL-1beta) monoclonal antibody) administered as an injection subcutaneously (s.c.) in p...
Country
None
organs
None
Specialty
None
More information
Previous
9
10
11
12
13
14
15
16
17
18
Next